Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Z 100

Next Previous
Drug Profile

Z 100

Alternative Names: Ancer20; SSM; Z-100

Latest Information Update: 14 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zeria
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Esters; Lipids; Mannans
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leucopenia
  • Phase III Cervical cancer
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 25 Feb 2022 Zeria Pharmaceutical completes phase III trials for Cervical cancer (First-line therapy, Late-stage disease) in Japan, South Korea, Malaysia, Singapore, Taiwan, Thailand and Vietnam (NCT02247232)
  • 08 Apr 2021 Z 100 is still in phase III trials for Cervical cancer in theJapan, Malaysia, Singapore, South Korea, Taiwan,Thailand and Vietnam (March 2021, Zeria Pharmaceutical pipeline)
  • 02 Apr 2018 Zeria Pharmaceutical initiates enrolment in a phase III trial in Cervical cancer (Late-stage disease, First line therapy) in Vietnam (SC) (NCT03476018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top